This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
I'm LongbridgeAI, I can summarize articles.Wall Street analysts downgraded five stocks on Wednesday: BTIG downgraded Ellington Financial (EFC) to Neutral; BofA downgraded Leidos (LDOS) to Neutral with a price target cut to $125; Goldman Sachs downgraded Ermenegildo Zegna (ZGN) to Neutral but raised its target to $14; William Blair downgraded Simulations Plus (SLP) to Market Perform; and Morgan Stanley downgraded ResMed (RMD) to Equal-Weight, lowering its target to $230.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- BTIG analyst Douglas Harter downgraded Ellington Financial Inc (NYSE:EFC) from Buy to Neutral. Ellington Financial shares closed at $13.67 on Tuesday. See how other analysts view this stock.
- B of A Securities analyst Mariana Perez downgraded Leidos Holdings, Inc. (NYSE:LDOS) from Buy to Neutral and cut the price target from $200 to $125. Leidos shares closed at $113.58 on Tuesday. See how other analysts view this stock.
- Goldman Sachs analyst Adrien Duverger downgraded Ermenegildo Zegna N.V. (NYSE: ZGN) from Buy to Neutral and raised the price target from $13.3 to $14. Ermenegildo Zegna shares closed at $14.49 on Tuesday. See how other analysts view this stock.
- William Blair analyst Max Smock downgraded Simulations Plus, Inc. (NASDAQ:SLP) from Outperform to Market Perform. Simulations Plus shares closed at $18.24 on Tuesday. See how other analysts view this stock.
- Morgan Stanley analyst David Bailey downgraded ResMed Inc. (NYSE:RMD) from Overweight to Equal-Weight and lowered the price target from $286 to $230. ResMed shares closed at $193.94 on Tuesday. See how other analysts view this stock.
Considering buying EFC stock? Here’s what analysts think:
Photo via Shutterstock